Recombinant Human Melanoma-Associated Antigen 4 (MAGEA4) Protein (His&Myc)

Name: Recombinant Human Melanoma-Associated Antigen 4 (MAGEA4) Protein (His&Myc)
Brand: Beta LifeScience
SKU: BLC-01979P
Availability: InStock

Greater than 85% as determined by SDS-PAGE.

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Product Overview

Description	Recombinant Human Melanoma-Associated Antigen 4 (MAGEA4) Protein (His&Myc) is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 85% as determined by SDS-PAGE.
Uniprotkb	P43358
Target Symbol	MAGEA4
Synonyms	Cancer/testis antigen 1.4 (CT1.4) (MAGE-4 antigen) (MAGE-41 antigen) (MAGE-X2 antigen)
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-10His&C-Myc
Target Protein Sequence	MSSEQKSQHCKPEEGVEAQEEALGLVGAQAPTTEEQEAAVSSSSPLVPGTLEEVPAAESAGPPQSPQGASALPTTISFTCWRQPNEGSSSQEEEGPSTSPDAESLFREALSNKVDELAHFLLRKYRAKELVTKAEMLERVIKNYKRCFPVIFGKASESLKMIFGIDVKEVDPTSNTYTLVTCLGLSYDGLLGNNQIFPKTGLLIIVLGTIAMEGDSASEEEIWEELGVMGVYDGREHTVYGEPRKLLTQDWVQENYLEYRQVPGSNPARYEFLWGPRALAETSYVKVLEHVVRVNARVRIAYPSLREAALLEEEEGV
Expression Range	1-317aa
Protein Length	Full Length
Mol. Weight	42.4 kDa
Research Area	Cancer
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Regulates cell proliferation through the inhibition of cell cycle arrest at the G1 phase. Also negatively regulates p53-mediated apoptosis.
Database References	HGNC: 6802 OMIM: 300175 KEGG: hsa:4103 STRING: 9606.ENSP00000276344 UniGene: Hs.37107
Tissue Specificity	Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testes and placenta.

Gene Functions References

MAGEA4 was positively correlated with TWIST1, and its knockdown inhibited EMT in TE3 cells. PMID: 28653599
Because of the significant correlation of MAGEA4 and indices of poor prognosis, the role of this CTA may be confirmed in Esophageal squamous cell carcinoma (ESCC) aggressiveness and metastasis. Therefore, MAGEA4 may be a promising therapeutic candidate for suppressing ESCC aggressiveness PMID: 30197348
Study shows that whereas MAGEA4 expression by itself may be indicative of a poor prognosis in primary lung cancer, its prognostic value depends entirely on its subcellular localization and on the p53 status. The accumulation of nuclear MAGEA4 expression without p53 expression is significantly associated with poor survival, implying that MAGEA4 inhibits apoptosis and increases tumorigenesis. PMID: 29901069
MAGE-A4 depletion from MAGE-A4-expressing cancer cells destabilizes RAD18. PMID: 27377895
Our results support...the potential utility of MAGEA4 as an ancillary diagnostic marker for synovial sarcoma PMID: 28744588
some autoantibodies, such as anti-MAGEA4, anti-CTAG1 or anti-TP53 and their combinations could possibly contribute to the development of cancer early detection tests (not necessarily restricted to gastric cancer) when being combined with other markers. PMID: 27140836
Anti-MAGEA4 exhibited the highest sensitivity for detecting early stage colorectal cancer (CRC) and advanced adenoma. PMID: 26909861
High MAGE-A4 expression is associated with Lung Cancer. PMID: 27793776
Results found concomitant overexpression of MAGEA4 and TWIST1 in esophageal squamous cell carcinoma (ESCC). Also, it showed a correlation between MAGEA4 and TWIST1 expression, which was found as indirect binding of TWIST1 to the E-boxes in the MAGEA4 promoter revealing transcriptional upregulation of MAGEA4 by TWIST1. PMID: 27533647
Results support the potential utility of NY-ESO-1, PRAME, and MAGEA4 as targets for immunotherapy and as ancillary prognostic parameters in synovial sarcomas. PMID: 27993576
CTAs (MAGE-A4, NY-ESO-1, MAGE-A10) were more likely expressed in patients with squamous cell carcinoma of the lung and when CTAs combined with CD133, they can be better prognostic factors. PMID: 26191258
HLA class I loss in smokers or patients with the MAGE-A4 gene was a prognostic factors in non-small cell lung cancer . PMID: 23124547
Expression of MAGE-A4 may make immunotherapeutic intervention possible in selected patients with thyroid cancer. PMID: 24238058
Detection of MAGE-4 transcripts in blood may help to predict the prognosis and monitoring of the response of HCV-infected hepatocellular carcinoma patients to therapy PMID: 22653756
Mage-A4 expression and serum identification is and potential therapeutic target in estrogen receptor negative breast cancer. PMID: 23172894
MAGEA4 promotes growth by preventing cell cycle arrest and by inhibiting apoptosis mediated by the p53 transcriptional targets. PMID: 22842486
High MAGE-4 gene expression is associated with metastases in hepatitis C virus patients complicated by hepatocellular carcinoma. PMID: 21452042
MAGE-A4 is identified as a specific biomarker of esophageal squamous cell carcinoma with a possible oncogenic role contributing to tumor progression. PMID: 21613820
novel HLA-A2-restricted T cell epitope derived from MAGE-4 was identified PMID: 21815906
High MAGE-A4 gene expression is associated with head and neck squamous cell carcinoma PMID: 20715104
Report immunohistochemical expression of MAGE-A4 in renal oncocytoma and chromophobe renal cell carcinoma. PMID: 20591578
positive expression in patients with non-small cell lung cancer is associated with poorer overall survival PMID: 19545928
MAGE-4 protein may have a role in development of hepatocellular carcinogenesis in cirrhotic patients PMID: 11985796
MAGE-A4 expression in bladder transitional cell carcinoma. PMID: 12209610
strong MAGE-A4 expression and to a lesser degree NY-ESO-1 expression is characteristic of the vast majority of uterine carcinosarcomas and a major subset of papillary serous carcinomas PMID: 12209997
MAGE-A4 binds to gankyrin and suppresses its oncogenic activity. PMID: 12525503
a cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis PMID: 14739298
MAGE-A4(143-151) and SAGE(715-723) are HLA-A2402-restricted CTL epitopes PMID: 16061876
Expression may represent potential targets for cancer immunotherapy in patients with non small cell lung carcinoma. PMID: 16596224
Expressed in a large part of epithelial skin tumors with predominantly scattered immunoexpression pattern in organ-transplant recipients. PMID: 17214847
Its expression is significantly associated with prognostic factors in poor outcome of the non-small cell lung cancer. PMID: 18982744
Overexpression of MAGE-A4 is associated with bladder cancer. PMID: 19533752

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.